SPECT agent shows promise for imaging metastatic HER2 breast cancer

03/31/2014 | MolecularImaging.net

Indium-111 ABY-025 with SPECT could be used to pinpoint human epidermal growth factor receptor type 2 expression in metastatic breast cancer lesions, even with ongoing HER2-targeted treatment, according to data from a first-in-human trial reported in the Journal of Nuclear Medicine. Rapid clearance allowed for production of high-contrast images within four to 24 hours, and low hepatic uptake could allow for better imaging of liver lesions than a previous agent.

View Full Article in:

MolecularImaging.net

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC